tirzepatide clinical trial enrollment vs semaglutide: A new battle in obesity treatment Reduction of prevalence of patients

M., Chang, C

Treating diabetes and obesity with GLP-1s and multireceptor agonists Glucagon-like peptide-1 receptor agonists (GLP-1 RAs or GLP-1s), also known as incretin mimics, bind to the GLP-1 receptor to increase insulin production and reduce blood glucose levels

I will say that this is a very different year when you think about what we focused on in the past, which are typically, you know, how do we resolve some of the barriers to vaccine access, how do we make sure that we can get vaccines in arms

No conversation about GLP-1s would be complete without addressing access and our cultural messaging around weight